GlassScriptPhysician profile
Paris Spanolias
NPI 1407956378
$2,963.55
in general payments reported to CMS, 2019-2025
26 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $17.98 · 2021: $19.57 · 2022: $304 · 2023: $521 · 2024: $658 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $513.49 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $457.39 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $454.24 | 2022-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.98 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $254.10 | 2022-2025 | Wegovy |
| Inspire Medical Systems, INC. | $188.55 | 2023-2025 | Inspire |
| Lilly USA, LLC | $120.98 | 2023 | Jardiance |
| Medtronic Vascular, INC. | $114.29 | 2019 | |
| Exact Sciences Corporation | $67.95 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $58.03 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $43.03 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $38.71 | 2025 | Symbravo, Auvelity |
| Watermark Medical, INC. | $34.44 | 2024 | |
| Mannkind Corporation | $26.21 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $25.69 | 2025 | Neffy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.46 | 2019 | |
| Sumitomo Pharma America, INC. | $20.84 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.62 | 2025 | Xifaxan |
| Corcept Therapeutics | $20.15 | 2025 | Korlym |
| Amgen INC. | $20.13 | 2025 | Repatha |
| Amarin Pharma, INC. | $19.57 | 2021 | |
| Pfizer INC. | $16.45 | 2025 | |
| Currax Pharmaceuticals LLC | $16.12 | 2022 | |
| Lucid Diagnostics INC. | $15.95 | 2025 | |
| Almatica Pharma LLC | $14.29 | 2025 | Loreev Xr |
| Echosens North America, INC. | $7.89 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paris Spanolias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.